Pfizer’s high-stakes sprint to build momentum in century-defining market

What began in early 2025 as a transformational transaction for Mayne Pharma has, by December, unravelled into a public dispute over obligations, regulatory conditions, and the future of the companies’ long-negotiated scheme of arrangement.

OncoSil Medical’s CEO and Managing Director, Nigel Lange, said, “This first commercial treatment in the UK is an important step forward for OncoSil and for patients living with pancreatic cancer.”

The Department of Health, Disability and Aged Care has clarified how the PBAC intends to address concerns over paediatric access to biologic therapies for Crohn’s disease and other immunological conditions, following a tense exchange at Senate Estimates last week.

The only problem? None of the new detail was provided when two senators asked directly, twice, on the public record last week, which begs at least one obvious question.

Australian immunotherapy developer Immutep has secured one of the most significant commercial partnerships in its history, signing a strategic collaboration and exclusive licensing agreement with India’s Dr. Reddy’s Laboratories.

Australia has become one of the first countries in the world to formally permit the use of nicotinamide mononucleotide, a widely discussed molecule in longevity science, in therapeutic products.

Australian scientists have identified, for the first time, specific genetic changes that sharply increase the risk of the most sight-threatening forms of age-related macular degeneration, offering a crucial lead for developing new therapies that could intervene before irreversible vision loss occurs.

Among the Auditor-General's findings is that a government official suggested that the agency's external financial advisors host and fund a celebratory event with health department officials to mark the signing of the manufacturing contract.

Australia risks falling further behind its global peers in access to life-changing medical technologies unless governments commit to faster, more modern regulatory and reimbursement pathways, according to a new report released today.

The release of positive five-year data comes at a critical moment in Australia, where the Medical Services Advisory Committee has recently issued a recommendation on HEMGENIX, and CSL has indicated it is unlikely to accept the outcome.

Australia’s allergy sufferers have gained a new treatment option with the launch of ARX-Fluticasone, the country's first generic fluticasone furoate nasal spray for allergic rhinitis.

The Pharmaceutical Society of Australia has confirmed a leadership transition, electing Professor Mark Naunton as its next National President and Bridget Totterman as Vice President Elect.

Daiichi Sankyo president and CEO Hiroyuki Okuzawa says the company is entering one of the most consequential phases in its 120-year history, as it prepares a new five-year plan built around global expansion, powerful technology platforms and an increasingly complex geopolitical environment.

The research, released by Cube as part of its new Inside Health Conversations digital insights series, shows a decisive shift that emotional resonance, not information alone, now determines whether health messages cut through. Australians want health communication that reflects their reality, not just their condition.

A turbulent round of Senate Estimates, highlighted by a heartbreaking exchange about a mother with two children battling Crohn’s disease. We canvass ‘MFN’ pricing risks, FOI controversies, ministerial travel blowouts and looming budget pressures that do not operate according to what might be a common understanding.

The PBAC has released the agenda for its December 2025 Intracycle Meeting, revealing a workload dominated by internal submissions and outstanding matters, while also triggering political scrutiny after it failed to include an item officials had publicly claimed would be considered next week.

Pfizer has announced Phase 3 data demonstrating that its investigational therapy, HYMPAVZI (marstacimab), delivers significant reductions in bleeding episodes in adults and adolescents living with hemophilia A or B who have developed inhibitors.

Algorae Pharmaceuticals (ASX:1AI) has taken a step forward in proving the real-world capability of its AI-driven drug-combination engine, following the release of independently generated validation data from the Peter MacCallum Cancer Centre.

"It is unconscionable that the Department was either deliberately misleading or did not have the correct information on when this important issue will be considered and an update delivered for those affected like Sarah and her son," Senator Ruston said.